Articoli correlati
Wegovy
Novo Nordisk obesity drug; its oral tablet form launched in French pharmacies from Monday, Nov. 2, becoming the first GLP-1 obesity treatment sold in France as a pill. Active ingredient is semaglutide; monthly cost is €169–€235 and it is not reimbursed at launch.